Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

#4, At the same time, Chinese researchers reportedly

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mick Member Profile
Member Level 
Followed By 2,660
Posts 868,978
Boards Moderated 236
Alias Born 09/04/00
160x600 placeholder
Filgotinib Demonstrates Durable Efficacy & Consistent Safety Profile at 52 Weeks in FINCH 1 & 3 Studies in Rheumatoid Arthritis Business Wire - 6/4/2020 1:29:00 AM
Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs Business Wire - 6/1/2020 4:05:00 PM
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19 Business Wire - 6/1/2020 8:30:00 AM
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymph... Business Wire - 5/29/2020 8:00:00 AM
Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplas... Business Wire - 5/29/2020 8:00:00 AM
Gilead Sciences, Arcus Biosciences Ink 10-Year Partnership Dow Jones News - 5/27/2020 8:07:00 AM
Gilead Sciences & Arcus Biosciences Establish 10-year Partnership to Co-develop & Co-commercialize Next-generation Cancer Imm... Business Wire - 5/27/2020 7:11:00 AM
Location Plays Big Role in Patient Access to First Covid-19 Drug Dow Jones News - 5/22/2020 10:53:00 AM
Correction to the Drug Pricing Article Dow Jones News - 5/21/2020 7:27:00 PM
Coronavirus Revives Debate Over Drug Pricing Dow Jones News - 5/21/2020 2:04:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2020 7:14:33 PM
Gilead, Galapagos: Filgotinib 200mg Achieved Primary Endpoints in Phase 2b/3 Trial Dow Jones News - 5/20/2020 5:08:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/20/2020 4:03:18 PM
Gilead & Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcer... Business Wire - 5/20/2020 4:03:00 PM
Coronavirus Vaccine Frontrunners Emerge, Rollouts Weighed Dow Jones News - 5/17/2020 5:59:00 AM
Hedge Funds Expect a Cure But Are Wary of Betting Big -- WSJ Dow Jones News - 5/15/2020 3:02:00 AM
Correction to Coronavirus Cure Investing Article Dow Jones News - 5/14/2020 10:36:00 PM
Why Big Investors Aren't Betting It All on a Coronavirus Cure -- 2nd Update Dow Jones News - 5/14/2020 6:14:00 PM
Why Big Investors Aren't Betting It All on a Coronavirus Cure -- Update Dow Jones News - 5/14/2020 4:50:00 PM
Why Big Investors Aren't Betting It All on a Coronavirus Cure Dow Jones News - 5/14/2020 3:05:00 PM
Gilead & Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting Business Wire - 5/13/2020 5:00:00 PM
Gilead's Remdesivir Tested With Other Drugs to Fight Covid-19 Dow Jones News - 5/13/2020 5:59:00 AM
Cipla in Licensing Pact With Gilead Sciences for Manufacturing, Distribution of Remdesivir Dow Jones News - 5/13/2020 12:05:00 AM
Mylan Strikes Licensing Deal for Therapy Aimed at Treating Covid-19 Patients Dow Jones News - 5/12/2020 5:12:00 PM
Correction to Jubilant Life Sciences License Article Dow Jones News - 5/12/2020 3:28:00 PM
mick Member Level  Wednesday, 02/05/20 11:10:05 AM
Re: mick post# 2888
Post # of 3956 
#4, At the same time, Chinese researchers reportedly have applied for a local patent on an experimental Gilead drug that they believe could help fight the novel coronavirus outbreak - and also significantly bolster Gilead's bottom-line going forward.

The Wuhan Institute of Virology – based in the central Chinese city at the epicenter of the epidemic – has applied for a patent in China for the use of Remdesivir, an antiviral therapy used to treat infectious diseases including Ebola and SARS.

The application was made on Jan. 21 along with a military academy, according to a Feb. 4 statement on the institute’s website.

Beijing has moved aggressively to contain the infection that has killed almost 500 people and infected nearly 25,000. If granted, Gilead will need to get Chinese patent owners on board when it wants to sell the drug for treating the novel coronavirus infection outside China.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist